Get the Stockscreener App
12.60
1.64%
-0.21
After Hours:
13.20
0.60
+4.76%
Pharming Group Nv Adr stock is traded at $12.60, with a volume of 25,503.
It is down -1.64% in the last 24 hours and down -26.23% over the past month.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
See More
Previous Close:
$12.81
Open:
$12.97
24h Volume:
25,503
Relative Volume:
1.44
Market Cap:
$889.88M
Revenue:
$376.88M
Net Income/Loss:
$2.52M
P/E Ratio:
415.84
EPS:
0.0303
Net Cash Flow:
$49.32M
1W Performance:
-2.48%
1M Performance:
-26.23%
6M Performance:
-22.51%
1Y Performance:
+20.00%
1-Day Range:
$12.34
$13.19
1-Week Range:
$11.84
$13.19
52-Week Range:
$9.5354
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
12.60 | 904.71M | 376.88M | 2.52M | 49.32M | 0.0303 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Canaccord Genuity | Buy |
| Dec-09-24 | Initiated | Jefferies | Buy |
Pharming Group Nv Adr Stock (PHAR) Latest News
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com India
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Pharming Group N.V. Investigated by the Portnoy Law Firm - GlobeNewswire
Pharming (NASDAQ: PHAR) updates 20-F with corrected CEO/CFO certifications - Stock Titan
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 33.9% in March - MarketBeat
Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright - defenseworld.net
HC Wainwright Estimates Pharming Group Q3 Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest - MarketBeat
HC Wainwright Predicts Pharming Group Q1 Earnings - MarketBeat
A2QLQY Stock Price and Chart — LS:A2QLQY - TradingView
Wainwright reiterates Pharming stock Buy rating on commercial growth - Investing.com
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Finviz
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Drop in Short Interest - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V.PHAR - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - GlobeNewswire Inc.
FY2025 EPS Estimates for Pharming Group Increased by Analyst - Defense World
Pharming shares surge as 2026 guidance tops analyst expectations - Investing.com
Pharming Group stock tumbles after FDA issues Complete Response Letter - Investing.com
Pharming Group (NASDAQ:PHAR) Sets New 1-Year HighTime to Buy? - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group stock hits 52-week high at 18.6 USD - Investing.com
Pharming Group Nv Adr Stock (PHAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):